Merck & Co., Inc. Again Reduces Price Of STOCRIN (efavirenz) For Patients In Least Developed Countries And Countries Hardest Hit By Epidemic
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc.1, today announced a reduction in the price of its HIV/AIDS medicine, STOCRIN (efavirenz), in the least developed countries of the world and those hardest hit by the epidemic.